Analysts Set GeoVax Labs, Inc. (NASDAQ:GOVX) Price Target at $14.20

GeoVax Labs, Inc. (NASDAQ:GOVX) has received a consensus rating of “Buy” from the seven analysts that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.20.

Several research firms have recently commented on GOVX. Alliance Global Partners initiated coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th. Finally, D. Boral Capital reissued a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a research note on Wednesday, December 18th.

Institutional Investors Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC bought a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Trading Down 1.5 %

Shares of NASDAQ GOVX opened at $2.60 on Tuesday. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The firm’s 50 day simple moving average is $2.43 and its two-hundred day simple moving average is $2.83.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same period in the prior year, the business posted ($4.80) EPS. On average, equities analysts anticipate that GeoVax Labs will post -4.49 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.